- Poster presentation
- Open Access
Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients
Critical Care volume 18, Article number: P408 (2014)
Endotoxin plays a crucial role in the pathogenesis of severe sepsis and septic shock (SS&SSh) . The aim of this study is to analyze the impact of extracorporeal endotoxin removal with polymyxin B hemoperfusion (PMX-DHP) (Toraymyxin®).
All patients admitted to our ICU between 1 April 2011 and 30 June 2013 who developed SS&SSh and underwent endotoxin activity assay (EAA) measurement were retrospectively evaluated.
During the study period, EAA was dosed in 100 patients. Eighty- one patients were affected by septic shock. The source of infection was identified in 70.4% of cases (45% abdominal) and the percentage of microbiologically confirmed episodes was 77% (81% Gram-negatives). The mortality rate was 49%. The mean EAA level was 0.66 ± 0.2, and in 66% of patients the value was higher than 0.6. No significant differences were found in terms of SAPS II (P = 0.32) and SOFA score (P = 0.67), according to EAA level (>/≤0.6). Patients with levels >0.6 presented a higher percentage of microbiologically confirmed infections (84% vs. 66%; P = 0.09). Thirty-two of 66 patients with EAA >0.6 were treated with Toraymyxin®. No complications leading to treatment interruption were recorded and a relevant decrease of cardiovascular SOFA score and lactate levels were observed 72 hours after treatment (P = 0.05 and P = 0.06, respectively). Source control and Toraymyxin® treatment resulted as the only modifiable factors improving the ICU survival rate (Table 1).
EAA is a rapid and reliable method to identify patients who may be treated with polymyxin B hemoperfusion. Source control and extracorporeal endotoxin removal have appeared as two effective interventions that should be implemented in the early management of patients with SS&SSh.
Cruz DN, Antonelli M, et al.: Early use of polymyxin B hemoperfusion in abdominal septic shock. The EUPHAS randomized controlled trial. JAMA 2009, 301: 2445-2452. 10.1001/jama.2009.856
About this article
Cite this article
Cutuli, S., De Pascale, G., Alicino, V. et al. Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients. Crit Care 18 (Suppl 1), P408 (2014). https://doi.org/10.1186/cc13598
- Survival Rate
- Effective Intervention
- Septic Shock
- Emergency Medicine